Tango Therapeutics, Inc.
TNGX
$10.08
-$0.34-3.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.28% | -42.84% | 10.10% | 15.18% | 15.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.28% | -42.84% | 10.10% | 15.18% | 15.67% |
| Cost of Revenue | -5.18% | 0.92% | 13.63% | 24.93% | 25.12% |
| Gross Profit | 31.08% | -20.99% | -15.13% | -29.46% | -29.82% |
| SG&A Expenses | 2.57% | 13.55% | 16.82% | 23.22% | 21.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.41% | 3.79% | 14.38% | 24.53% | 24.35% |
| Operating Income | 21.02% | -18.75% | -15.64% | -27.52% | -27.32% |
| Income Before Tax | 18.49% | -25.00% | -18.47% | -28.03% | -23.31% |
| Income Tax Expenses | -47.57% | -1.71% | 16.09% | 55.22% | 49.28% |
| Earnings from Continuing Operations | 18.54% | -24.96% | -18.46% | -28.07% | -23.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.54% | -24.96% | -18.46% | -28.07% | -23.34% |
| EBIT | 21.02% | -18.75% | -15.64% | -27.52% | -27.32% |
| EBITDA | 21.35% | -19.11% | -15.92% | -28.04% | -27.80% |
| EPS Basic | 21.77% | -17.33% | -7.26% | -9.47% | -5.39% |
| Normalized Basic EPS | 24.33% | -14.61% | -4.54% | -8.52% | -5.81% |
| EPS Diluted | 20.74% | -17.44% | -7.37% | -9.58% | -5.50% |
| Normalized Diluted EPS | 23.62% | -14.61% | -4.54% | -8.52% | -5.81% |
| Average Basic Shares Outstanding | 4.33% | 6.64% | 11.52% | 16.96% | 16.78% |
| Average Diluted Shares Outstanding | 5.94% | 6.64% | 11.52% | 16.96% | 16.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |